A Serious Adverse Event (SAE) is an untoward medical occurrence that occurs during a clinical trial and meets specific seriousness criteria. According to ICH E2A and GCP guidelines, an adverse event is considered serious if it results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is otherwise considered medically significant based on medical judgment. The SAE reporting system is a core element of the pharmacovigilance system in clinical trials, ensuring that safety signals are identified early, evaluated, and communicated to the competent authorities and ethics committees. The correct differentiation between SAE, SAR, and SUSAR is of central regulatory importance.
Differentiation from other safety terms
An SAE must be distinguished from related safety terms. An Adverse Event (AE) is any untoward medical occurrence that occurs after the administration of an investigational medicinal product (IMP), regardless of severity or causality assessment. An SAE is an AE that additionally meets the seriousness criteria mentioned above. A Serious Adverse Reaction (SAR) is an SAE for which a causal relationship with the investigational medicinal product is suspected. A Suspected Unexpected Serious Adverse Reaction (SUSAR) occurs when the SAR is also not listed as a known side effect in the Investigator’s Brochure (IB) or the product information.
The distinction is regulatory significant: while SAEs must be reported to the sponsor within 24 hours, SUSARs are subject to expedited reporting deadlines to authorities (7 days for fatal or life-threatening SUSARs, 15 days otherwise). The causality assessment (related/not related) is the responsibility of the investigator, but can be independently assessed by the sponsor.
Reporting obligations and timelines
The SAE reporting chain is clearly defined in GCP guidelines and EU Regulation 536/2014. The investigator is obliged to report SAEs immediately—usually within 24 hours of becoming aware of them—to the sponsor. The sponsor evaluates the SAE, checks for expectedness and causality, and, if necessary, submits a SUSAR report to the competent authority (e.g., BfArM, PEI) and the ethics committee. The EU’s Clinical Trials Information System (CTIS) centralizes these reporting obligations for all participating member states.
Expedited reports for SUSARs are submitted via EudraVigilance (for IMP trials) or directly to the national authority. Annual safety reports (Development Safety Update Report, DSUR) summarize all SAE and SUSAR reports for a reporting period and are prepared by sponsors in accordance with ICH E2F. Reporting obligations also apply to trials conducted outside the EU if the investigational medicinal product is intended for EU marketing authorization.
SAE management and documentation
SAE management in clinical trials includes the complete documentation of all relevant information in the Case Report Form (CRF) and in the source documentation. Each reported SAE is recorded with the following information: description of the event, start and end date, severity, causality assessment, actions taken, outcome, and any connection to the study protocol (e.g., study-related procedure). Incomplete or delayed SAE reports are among the most frequent findings during GCP inspections.
Responsibility for SAE follow-up lies with the investigator, who documents the course of the event until its resolution or stabilization. The sponsor and the CRO monitor the SAE reporting rate and quality as part of clinical monitoring. In multicenter trials, the sponsor consolidates all SAE reports centrally and ensures correct and timely forwarding to authorities.
Relevance for clinical trials
SAEs are a central element of the safety management system in clinical trials. Their complete and timely recording protects trial participants, ensures the integrity of the safety database, and enables the regulatory required benefit-risk assessment. The Data Safety Monitoring Board (DSMB) evaluates SAE data in regular interim analyses and can recommend the termination of the trial in the event of an unexpected increase in serious events.
For full-service CROs like mediconomics, a robust SAE management system is a prerequisite for GCP-compliant trial conduct. Standard Operating Procedures (SOPs) for the SAE reporting chain, training for investigator teams, and electronic SAE tracking systems ensure that no reportable events are overlooked. In risk-based monitoring according to ICH E6(R3), the SAE reporting rate is one of the critical data points that is checked as a priority during every monitoring activity.
Frequently Asked Questions (FAQ)
What is the difference between an SAE and an AE?
An Adverse Event (AE) is any untoward medical occurrence that occurs after the administration of the investigational medicinal product. An SAE is an AE that additionally meets at least one of the defined seriousness criteria: death, life-threatening, hospitalization, permanent disability, congenital anomaly, or medical significance according to the physician’s judgment. Every SAE is therefore also an AE, but not every AE is an SAE. The severity assessment (mild/moderate/severe) must be strictly distinguished from the classification as an SAE.
Within what period must an SAE be reported?
Investigators must report SAEs to the sponsor within 24 hours of becoming aware of them. The sponsor forwards a SUSAR report, if necessary, to the competent authority and the ethics committee within 7 days (in the case of death or life-threatening events) or 15 days (in all other cases). In CTIS, the reporting deadlines are uniformly regulated for all EU member states.
What happens if an SAE is not reported on time?
Delayed or omitted SAE reports constitute serious GCP violations. They can lead to findings during inspections by BfArM, PEI, or EMA, which in the worst case can result in the exclusion of the affected trial data from the marketing authorization assessment. Sponsors and investigators may also face administrative consequences under the German Medicines Act (AMG) or EU Regulation 536/2014.